Clemizole

Research use only, not for human use.

An H1 histamine receptor antagonist that substantially inhibits HCV replication by suppression of NS4B's RNA binding (IC50=24 nM) with little toxicity for the host cells.

An H1 histamine receptor antagonist that substantially inhibits HCV replication by suppression of NS4B's RNA binding (IC50=24 nM) with little toxicity for the host cells; also selectively and efficiently blocks TRPC5 currents and Ca(2+) entry with IC50 of 1-1.3 uM, 6-fold selectivity over TRPC4β (IC50 = 6.4 μM), and almost 10-fold selectivity over TRPC3 (IC50 =9.1 uM) and TRPC6 (IC50=11.3 uM), only very weakly affects TRPM3, TRPM8 and TRPV1, V2, V3, and V4 channels. HCV Infection Phase 2 Clinical

Clemizole; NSC 46261; NSC-46261; NSC46261

Membrane Transporter/Ion Channel

TRP/TRPV Channel

NS4BH1histaminereceptor

Infection

HCV Infection

442-52-4

325.84

C19H20ClN3

>98% (HPLC)

10 mM in DMSO

ClC1=CC=C(C=C1)CN2C3=CC=CC=C3N=C2CN4CCCC4

1H-Benzimidazole, 1-[(4-chlorophenyl)methyl]-2-(1-pyrrolidinylmethyl)-

(-20℃)

With Ice Pack

≥ 2 years